Literature DB >> 11020445

Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism.

S E Shadle1, B P Bammel, B J Cusack, R A Knighton, S J Olson, P S Mushlin, R D Olson.   

Abstract

Anthracyclines, such as daunorubicin (Daun), and other quinone-containing compounds can stimulate the formation of toxic free radicals. The present study tests the hypothesis that the quinone moiety of Daun, by increasing free-radical production, disrupts sarcoplasmic reticulum (SR) function and thereby inhibits myocardial contractility in vitro. We compared Daun with its quinone-deficient analogue, 5-iminodaunorubicin (5-ID), using experimental interventions to produce various contractile states that depend on SR function. At concentrations of Daun or 5-ID that did not alter contractility (dF/dt) of steady-state contractions (1 Hz) in electrically paced atria isolated from adult rabbits, only Daun significantly attenuated the positive inotropic effects on dF/dt of increased rest intervals (PRP; post-rest potentiation) or increased stimulation frequencies. Attenuation was to 98+/-6% at 1 Hz, and 73+/-8 and 67+/-8% for 30 and 60 sec PRP, respectively, and 73+/-3 and 63 +/-3% at 2 and 3 Hz, respectively, for 88 microM Daun (P<0.05, vs pre-drug baseline values, mean +/- SEM). These effects of Daun were similar to those of caffeine (2 mM), an agent well known to deplete cardiac SR calcium. We also examined the effect of Daun in isolated neonatal rabbit atria, which lack mature, functional SR; Daun did not alter the force-frequency relationship or PRP contractions. Additional studies in Ca(2+)-loaded SR microsomes indicated that both Daun and 5-ID opened Ca(2+) release channels, with Daun being 20-fold more potent than 5-ID in this respect. Neither anthracycline, however, induced free-radical formation in SR preparations (assayed via nicking of supercoiled DNA) prior to stimulating Ca(2+) release. Thus, our results indicate that Daun impairs myocardial contractility in vitro by selectively interfering with SR function; the quinone moiety of Daun appears to mediate this cardiotoxic effect, acting through a mechanism that does not involve free radicals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020445     DOI: 10.1016/s0006-2952(00)00458-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells.

Authors:  Mohammad H El-Dakdouki; David C Zhu; Kheireddine El-Boubbou; Medha Kamat; Jianjun Chen; Wei Li; Xuefei Huang
Journal:  Biomacromolecules       Date:  2012-03-13       Impact factor: 6.988

Review 2.  Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging.

Authors:  Gurusher Singh Panjrath; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

3.  Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model.

Authors:  Nicole E Frank; Barry J Cusack; Todd T Talley; Gerald M Walsh; Richard D Olson
Journal:  Invest New Drugs       Date:  2016-08-31       Impact factor: 3.850

4.  Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.

Authors:  Dinesh Vyas; Nicolas Lopez-Hisijos; Sulakshana Gandhi; M El-Dakdouki; Marc D Basson; Mary F Walsh; X Huang; Arpita K Vyas; Lakshmi S Chaturvedi
Journal:  J Nanosci Nanotechnol       Date:  2015-09

Review 5.  Imaging of early modification in cardiomyopathy: the doxorubicin-induced model.

Authors:  Mohamed Aissiou; Delphine Périé; Farida Cheriet; Nagib S Dahdah; Caroline Laverdière; Daniel Curnier
Journal:  Int J Cardiovasc Imaging       Date:  2013-06-07       Impact factor: 2.357

6.  Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors.

Authors:  Sarah A Holstein; James C Bigelow; Richard D Olson; Robert E Vestal; Gerald M Walsh; Raymond J Hohl
Journal:  Invest New Drugs       Date:  2015-02-21       Impact factor: 3.850

7.  Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow.

Authors:  Amanda J Stolarz; Mustafa Sarimollaoglu; John C Marecki; Terry W Fletcher; Ekaterina I Galanzha; Sung W Rhee; Vladimir P Zharov; V Suzanne Klimberg; Nancy J Rusch
Journal:  J Pharmacol Exp Ther       Date:  2019-08-22       Impact factor: 4.030

8.  SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway.

Authors:  Gui'e Xie; Xun Zhu; Qing Li; Minghui Gu; Zhenjian He; Jueheng Wu; Jun Li; Yongcheng Lin; Mengfeng Li; Zhigang She; Jie Yuan
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

9.  Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo.

Authors:  Shao-hui Zhang; Wen-quan Wang; Jia-ling Wang
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

10.  Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A.

Authors:  Amy D Hanna; Alex Lam; Steffi Tham; Angela F Dulhunty; Nicole A Beard
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.